Modality
mAb
MOA
TYK2i
Target
CD47
Pathway
Fibrosis
GAIPF
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
Aug 2020
→ May 2028
Phase 2Current
NCT07118824
1,487 pts·IPF
2022-12→2028-02·Not yet recruiting
NCT04308439
1,708 pts·GA
2020-08→2028-05·Not yet recruiting
3,195 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-02-151.9y awayPh2 Data· IPF
2028-05-112.1y awayPh2 Data· GA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Not yet…
P2
Not yet…
Catalysts
Ph2 Data
2028-02-15 · 1.9y away
IPF
Ph2 Data
2028-05-11 · 2.1y away
GA
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07118824 | Phase 2 | IPF | Not yet recr... | 1487 | CfB |
| NCT04308439 | Phase 2 | GA | Not yet recr... | 1708 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |